{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/george-d-demetri/", "hostname": "dana-farber.org", "description": "George D. Demetri, MD - Medical Oncology. Dr. Demetri is director of the Center for Sarcoma and Bone Oncology at DFCI, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and executive director for Clinical and Translational Research at the Ludwig Institute for Cancer Research.", "sitename": "George D. Demetri, MD - Dana-Farber Cancer Institute", "date": "2012-04-06", "cleaned_text": "Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in Cell Genom. 2023 12; 3(7):100321. View the anti-tumour activity of CDK4/6 inhibition in 11; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36175617) Biomarker correlates with response NY-ESO-1 TCR T cells in patients with synovial 2022 09 observational in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022 Nov; 110:102455. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36031697) Real-world survival with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other inhibitors. PLoS One. 2022; 17(8):e0270571. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35939431) Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Med. 2023 01; 12(1):170-178. View in: Modeling of Leiomyosarcoma Identifies to Transcriptional CDK Inhibitors through Antagonism of in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35325095) Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. 2022 May 13; 28(10):2196. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35553647) Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. Clin of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Manag Res. 2021; 13:5523-5533. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34285574) Pharmacokinetic-pharmacodynamic schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer. 2021 08; 125(5):687-698. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34140638) Cardiac combination with pegylated liposomal doxorubicin in patients with sarcomas and 06; 10(11):3565-3574. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33960681) from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33910263) Patient-reported outcomes from STARTRK-2: a II basket study of entrectinib for ROS1 fusion-positive non-small-cell Sarcoma: An Unbreakable Bond (ESMO Sarcoma and GIST Symposium 2020 Industry Satellite Symposium, Milan, February 4, 2020). Oncology. 2021; 99 Suppl 1:1-2. View in: Evidence and Real-World Data to Decision-Making in the Management of Soft Suppl Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Solid Cancer Res. 2021 07 01; 27(13):3556-3566. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33820780) Identification and Therapeutic Targeting of GPR20, Selectively Expressed Gastrointestinal Stromal [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33451979) Molecular Characterization Colorectal Cancers Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clin Cancer Res. 2021 loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33035459) tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the Gene-Expression of and Uterogenic Subtypes. Mol Cancer Res. 2020 09; 18(9):1302-1314. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32518213) The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. Expert Rev Anticancer Ther. 2020 Soft-Tissue Sarcomas: and Clinical (Basel). 2020 Mar 23; 12(3). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32210091) Larotrectinib, a for and pediatric tropomyosin receptor Future Oncol. 2020 Mar; 16(9):417-425. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32129093) Response and and and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020 02; 26(2):181-187. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32042194) Activity of larotrectinib in Jun; A II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32. metastatic NTRK fusion-positive solid tumours: integrated analysis of three gastrointestinal analysis patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32085042) Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013 Feb; 24(2):537-542. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32018433) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated sunitinib. Ann Oncol. 2012 Dec; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32018827) Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized Mar; 23(3):771-776. View syndrome observed with adoptive of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. Cancer. 2019 11 08; 7(1):296. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31703609) Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother drives oncogenic SDH-deficient GIST. Nature. 2019 Oct 16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31618758) Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31503332) Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31471313) The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31290566) Safety and Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup Complementary activity of kit mutations in imatinib-resistant gastrointestinal Br J Cancer. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31123346) Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or 2019 08 01; 125(15):2610-2620. Patterns lung cancer Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Complementary activity of secondary kit mutations in imatinib-resistant gastrointestinal Enhancer Domains in Gastrointestinal Stromal KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 03 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30554195) of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or Oncol. 09 inhibitor, advanced solid tumors: a phase 1 dose-escalation Gastrointestinal stromal tumor enhancers support factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29866822) Efficacy of Larotrectinib Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29466156) Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Invest New Drugs. 2018 06; 36(3):476-486. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29177975) SMARCB1 is required for widespread of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a 3, Oncol. 2017 09; 146(3):531-537. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28651804) Defining the Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : 01; 3(5):597-599. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28334361) MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. in: Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28228279) Advances and controversies in the of soft sarcomas. Future Oncol. 2017 Jan; 13(1s):3-11. 2016 11; 36(6):462-467. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27987546) Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium. Semin Nephrol. 10 10; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27458282) Long-term results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of A of imatinib in the treatment of gastrointestinal stromal [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26865352) Eribulin versus in liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 2016 Apr 16; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26874885) Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use BMC Cancer. 2016 Impact of imatinib rechallenge stromal tumours: Sub-analysis of the placebo-controlled, randomised J Cancer. 2016 Jan; 52:201-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26699729) Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 2015 Dec 08; 132(23):2248-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26644247) Efficacy and Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Clin Oncol. 2016 Mar 10; 34(8):786-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26371143) Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications eribulin in patients (pts) with leiomyosarcoma (LMS) and sarcoma 20; 33(18_suppl):LBA10502. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28147724) in the Clinical Management of Gastrointestinal Stromal Tumors: An [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25882987) Ombrabulin plus cisplatin in patients with advanced soft-tissue sarcomas after and ifosfamide May; 16(5):531-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25864104) A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer. 2015 Mar 25; imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol. 2015 Oct; 20(5):905-12. View in: patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use sunitinib. Cancer. 2015 05 01; 121(9):1405-13. View a histone deacetylase inhibitor, in combination with doxorubicin Cancer. 2015 Apr 15; 121(8):1223-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25536954) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25374341) Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. 2014 Aug 08; 14:575. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25102852) c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue 2014 Sep; 13(9):2184-93. View in: cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014 Oct 15; 120(20):3154-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24923260) Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014 Aug; 50(12):2162-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24930624) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun; 19(6):669-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24821824) Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6. View in: and KIT Polyclonal Primary Imatinib Resistance in GI Stromal Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24638003) Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and 2014 Mar; 50(5):981-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24388774) A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib sunitinib. Ann Oncol. 2014 Jan; 25(1):236-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24356634) International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014 Mar; 50(4):679-89. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24295638) Phase 2 trial of aromatase with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24222211) Nov; 14(12):1175-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24140183) A of inhibitor retaspimycin hydrochloride (IPI-504) 19(21):6020-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24045182) Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013 Oct 01; 109(7):1717-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24022187) Long-term results of primary gastrointestinal stromal tumor: ACOSOG intergroup View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23860199) trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study. J amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. 31(26):3182-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23775962) Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 01; 31(19):2485-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23715582) Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013 Jul 15; 19(14):3796-807. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23714727) Genome-wide functional screening identifies CDC37 crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal Apr 03; 33(14):1872-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23584476) First-in-human phase I trial of of a novel multikinase inhibitor, incorporating translational proof-of-mechanism 15; 19(4):909-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23403628) Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013 Jun; 24(6):1703-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23385197) Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Eur J Cancer. 2013 May; 49(7):1515-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23333057) Efficacy and safety of tumours after international, multicentre, randomised, placebo-controlled, Jan 26; 381(9863):295-302. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23177515) Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013 Feb; 24(2):537-542. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23117071) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22858558) Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012 Oct; primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. and Metastatic/recurrent Operable Long-term Follow-up 2012 antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012 Nov; 48(16):3036-44. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22749255) Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Cancer Res. 2012 Jun 01; 18(11):3170-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22661587) Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22614970) Tivantinib (ARQ 197), a selective of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 Cancer. May 19; 379(9829):1879-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22595799) A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012 Nov 01; 118(21):5403-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22570147) Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012 May 30(15):1849-56. View in: lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18; 483(7391):613-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22425996) Imaging features of Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib Ann Oncol. 2012 intra-tumoral pressure and circulating biomarkers in advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin alone: a phase I/II open-label and Cancer. 2012 Mar; 48(4):547-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22240283) How to decide whether to offer and use \"nonstandard\" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and data. Am Soc Clin Oncol Educ model: physician-patient collaboration in online communities and the clinical practice of oncology. Am Soc Clin Oncol Educ Book. and metastatic/recurrent operable long-term follow-up study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 01 27; 108(39):16386-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21930930) Clinical presentation Group-directed trial (S0505) of sorafenib in advanced soft sarcomas. Cancer. 2012 Feb 01; 118(3):770-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21751200) Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized 2012 Mar; trial neoadjuvant/adjuvant (IM) advanced primary and metastatic/recurrent [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28021247) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Hsp90 ganetespib (STA-9090) in patients (pts) with [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28021119) A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 of histopathologic discordance sarcoma with implications for clinical care. Oncol. 2011 May 20; 29(15_suppl):10065. View in: regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). Clin Oncol. 2011 May 20; 29(15_suppl):10050. View evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3052. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28022582) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28021121) A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs. 2012 Jun; 30(3):1193-202. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21484250) Differential properties [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21419931) (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):871-9. in and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 04; 108(1):314-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21173220) Strong expression stromal tumors without IGF1R genomic Crizotinib in ALK-rearranged 363(18):1727-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20979472) The neuroblastoma-associated F1174L ALK resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010 Dec 15; of with imatinib in NCCN Task Force update on the management with gastrointestinal stromal in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20457867) Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med. 2010 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20121601) in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10; 28(5):835-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20048174) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010 Jan 01; 116(1):210-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19862817) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: trabectedin (ecteinascidin-743) with skin and Oncol. 2009 Nov 20; 27(33):e198-200. View dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6232-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19789325) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib Cancer Res. 2009 Sep 15; 15(18):5902-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19737946) Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Res. 2009 Sep 15; 15(18):5869-77. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19737953) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. 2009 Sep View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19723647) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin 2009 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19664491) Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19647426) Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19326424) Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):10502. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27963690) Real patterns of tumor Clin Oncol. 2009 May 20; 27(15_suppl):e15602. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27962678) A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):e13510. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27961298) evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):3501. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27961289) Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and 2009 May of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):e14539. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27963557) Final a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):3564. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27961683) Multicenter trial of nongastrointestinal stromal tumor Imatinib plasma levels are clinical benefit patients with unresectable/metastatic gastrointestinal stromal View Clinical evaluation of continuous daily sunitinib in patients with advanced gastrointestinal stromal after Eur J Cancer. 2009 Jul; 45(11):1959-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19282169) Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. Clin Adv unique drug resistance to imatinib sunitinib in gastrointestinal stromal tumor patients. Proc 2009 Feb 03; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19164557) Phase II trial of neoadjuvant/adjuvant (IM) advanced primary and metastatic/recurrent cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced Oncol. 2008 Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov secondary kinase genotypes correlate with the and clinical activity in imatinib-resistant gastrointestinal stromal in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18955458) Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008 CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Res. 14(17):5626-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18765557) of [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18706807) Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene. 2008 Sep 18; 27(42):5624-34. A phase I-II study of everolimus (RAD001) in with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (PK) and clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST). 26(15_suppl):4523. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27949093) dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid Clin Oncol. 2008 May 20; 26(15_suppl):3553. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27949658) A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948505) Inhibition shock (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948417) Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol. 2008 May 20; (CDD) (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10533. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948539) Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S. J Clin Oncol. 2008 May 20; 26(15_suppl):10573. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948304) Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. 2008 May 20; 26(15_suppl):10524. in: response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. J Clin Oncol. 2008 May 20; 26(15_suppl):10529. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948364) Phase II intergroup study of (S) in soft tissue sarcomas Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with tyrosine Res. 2008 A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18270341) Long-term results from a II trial of standard- versus higher-dose patients with 26(4):620-5. View randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. May; 34(3):223-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18234424) Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Oncol. 2008 Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest. 2007 Dec; 117(12):3650-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18060025) mesylate in patients with stromal of View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17896156) patients with metastatic gastrointestinal stromal tumors. Clin Pt 1):5398-405. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17875769) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17761719) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007 Sep; 6(9):734-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17690708) with gastrointestinal stromal tumor (GIST)--update of NCCN stromal tumor: PI3-kinase/AKT is a crucial 29; 26(54):7560-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17546049) Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 01; 109(9):1863-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17385194) KIT oncoprotein interactions angiogenesis and clinical features in patients with sarcoma. Cancer. 2007 Mar 01; 109(5):813-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17265525) High-throughput oncogene mutation profiling 2007 Mar; 39(3):347-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17293865) Myeloid [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17256054) Cost effectiveness cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ. 2007; 22(1):21-4. View in: patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17088579) Clin Cancer 2006 Oct 1):6205-6; author reply 6206-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17062700) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised Lancet. 2006 Oct 14; 368(9544):1329-38. View in: Heat shock protein 90 inhibition gastrointestinal Cancer Res. 2006 66(18):9153-61. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16982758) Molecular correlates [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16954519) 20; 24(18_suppl):9519. (pts) imatinib (IM)-refractory Early results from a \"treatment-use\" 2006 Jun 20; 24(18_suppl):9540. Long-term a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib Oncol. 2006 Jun 20; 24(18_suppl):9528. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952792) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9513. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952838) Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9505. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952813) A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952790) Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27955213) Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9532. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952786) Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Clin Oncol. 2006 Jun 20; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27952818) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16710031) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16682719) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). with daily intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006 May; 42(7):864-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16503137) Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Oncol. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16316613) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006 Oct; 63(1-2):104-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16242898) Update soft multicenter phase II and pharmacokinetic study. 20; 23(24):5484-92. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16110008) oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: 2005 Jun; 23(16_suppl):9033. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27945575) in sarcoma and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) metastatic SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 23(16_suppl):9034. View in: study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue Oncol. genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal 23(16_suppl):7. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27946616) Results from a continuation trial SU11248 in patients (pts) with imatinib (IM)-resistant of in patients (pts) failure of imatinib for metastatic J patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol. in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. with the ZNF9, TRAP150, and OMD mesylate. Radiology. 2005 Jun; 235(3):892-8. View for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005 Apr; 16(4):566-78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15781488) Nursing of as therapy stromal of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin 2005 Jan 15; 11(2 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15701856) Recombinant 2004 Nov; 15(11):1667-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15520069) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J 2004 Oct study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Res. 2004 Sep constitutive activation in gastrointestinal stromal tumors Res. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15289315) Combination signal transduction oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Jul 15; (pts) with metastatic with clonal evolution mesylate [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28013747) Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol. 2004 22(14_suppl):9009. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28013692) Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells. (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28013625) Clonal evolution of resistance to (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new Clin Oncol. 2004 Jul 22(14_suppl):3010. View in: computerized tomography (CT) an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors Oncol. 2004 Jul in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28015171) Effects of cessation of imatinib (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized gastrointestinal stromal tumor (GIST)--expansion and update of NCCN Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb 15; 100(4):859-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14770445) and KIT ligand in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr 15; 103(8):2929-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15070666) Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14706663) Dynamic infrared imaging of newly lymphoma Gallium-67 and Fluorine-18 fluorodeoxyglucose sarcoma treated in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14676103) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14645423) OncoloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease. Eur J Cancer. 2003 Sep; 39(14):1976-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12957451) Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Aug 15; 98(4):832-40. in: troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12846423) Soft tissue sarcomas of adults: the Clin Cancer Res. 2003 Jun; 9(6):1941-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12796356) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12637460) Multicenter II study of oral bexarotene for patients with metastatic breast cancer. J Mar discussion Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep. 2002 of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1115-24. of subtype in [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12228211) A II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9. View Identification and treatment of chemoresistant in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12528773) in advanced gastrointestinal stromal tumors. N 2002 Aug 15; 347(7):472-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12181401) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12209734) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12094371) US in soft Drugs. 2002 May; 13 Suppl 1:S7-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12173492) Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12020395) inhibitor Incel (biricodar; VX-710) in combination advanced refractory to paclitaxel. Clin Cancer Res. 2002 Mar; 8(3):670-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11895894) Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90. View in: biricodar (VX-710) with concurrent doxorubicin in patients with soft tissue sarcoma. Clin Cancer Res. 2002 Feb; 8(2):383-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11839653) GIST 1, chemotherapy 0, with a brand new hitter up next. Cancer Invest. 2002; 20(5-6):853-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12197245) A phase II and pharmacokinetic study of ecteinascidin in patients View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12490740) Comparable of epoetin for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis 2002; 7(2):126-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11961196) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15; Suppl 2):72-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11760562) Targeting c-kit mutations tumors: scientific rationale therapeutic tumor c-KIT biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11526490) Response to chemotherapy and predictors survival in rhabdomyosarcoma. Ann Surg. 2001 with a metastatic tumor. N Engl J 344(14):1052-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11287975) A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr; 84 Suppl 1:17-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11308270) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer. 2001 Apr; 84 Suppl 1:31-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11308272) Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb; 7(2):231-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11234874) A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1):121-6. View in: platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2000 Nov; 26(10):1083-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11108307) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 18(20):3558-85. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11032599) 2000 Oct; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11905672) Effects of ligand activation of receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A. 2000 Sep 26; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10984506) Medical Mar; 156(3):791-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10702394) Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10526294) Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999 Jul; 230(1):79-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10400040) 96(7):3951-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10097144) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9779721) Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9690531) Major developments in the understanding treatment of sarcomas in 1998 Jul; 12(7A):183-218. View of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer 15(2):674-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9053493) NCCN Small-Cell Practice Guidelines. The National Cancer Network. Oncology (Williston in Suppl 6):22-6. human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 1996 Jun 01; 183(6):2681-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8676090) The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer. Pharmacotherapy. 1996 tumor size, margin resection, and mitotic activity for survival. J Clin Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. 1996 Feb; 36(2):160-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8614968) Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol North Am. 1995 Aug; 9(4):765-85. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7490240) Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy. Chest. 1995 Jun; 107(6 Suppl):255S-260S. View in: factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer. 1994 Oct 01; 74(7):1887-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7521785) Therapy with recombinant human erythropoietin patients with syndromes. Leuk Res. 1994 Oct; 18(10):769-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7934135) recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol. 1994 Aug; 87(4):678-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7986706) Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol. 1994 May; 87(1):153-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7947240) Stem cell factor hematopoiesis. Oncology. 1994 Mar-Apr; 51(2):205-14. View in: The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer. Hematol Oncol Clin North Am. 1994 Feb; 8(1):233-49. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8150782) Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993 Aug; 4(4):415-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8101563) Impact of hematopoietic growth factors on the management of small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):427S-432S. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8384974) Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1382921) 1991 Dec 01; 78(11):2791-808. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1720034) Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine Invest. Oct; 86(4):1261-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2212010) The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15; 76(4):716-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2200537) Hematopoietic growth May; 8(5):761-4. Biol The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 3.5-kb macrophage colony-stimulating factor transcript in human myeloma 1989 Dec 01; 143(11):3543-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2685119) Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 01; 56(3):425-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2617479) A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in View in: Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15; 74(3):940-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2787682) Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins. J Exp Med. 1989 Jul 01; 170(1):123-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2473156) Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med. 1989 Jun 01; 169(6):2257-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2499657) Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989 Apr 05; 264(10):5700-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2647723) In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia "}